Consideration Of The Concordance Rate Of 22c3 And 28-8 Antibody In Nsclc And Its Relation To The Effect Of Nivolumab.

143Background: Anti-PD-1 antibodies (Abs) have improved survival significantly in patients (pts) with advanced non-small cell lung cancer (NSCLC). Depending on the extent of PD-L1 expression, these drugs have become the standard care of initial treatment and 2nd line therapy. However, PD-L1 expression has not yet been recognized as a robust biomarker. Currently, two Anti-PD-1 Abs (Nivolumab, Pembrolizumab) are commercially available in Japan, but have each diagnostic immunohistochemical (IHC) assays (22C3 and 28-8Ab), respectively. The concordance rate of these assays is not yet well understood and the effect of these agents in concordance and inconsistency cases are also unknown. Based on these background, we explored the concordance rate of 22C3 and 28-8 Ab and its relation with the effect of Nivolumab (Nivo). Methods: We investigated the concordance rate of 22C3 and 28-8 as well as treatment effect and response of 24 advanced NSCLC pts treated in Kansai Medical University Hospital from December 2015 an...